GDC-0853 represses NF-κB–dependent gene transcription. CLL patient cells were treated with 1 µM BTK inhibitor for 72 hours with or without anti-IgM stimulation and assessed for gene expression changes of NF-κB targets by RT-PCR (N = 8). **P ≤ .01; ***P ≤ .001.